Opportunities and challenges of proteomics in pediatric patients: Circulating biomarkers after hematopoietic stem cell transplantation as a successful example

Sophie Paczesny, Christine Duncan, David Jacobsohn, Robert Krance, Kathryn Leung, Paul Carpenter, Catherine Bollard, Jamie Renbarger, Kenneth Cooke

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Biomarkers have the potential to improve diagnosis and prognosis, facilitate-targeted treatment, and reduce health care costs. Thus, there is great hope that biomarkers will be integrated in all clinical decisions in the near future. A decade ago, the biomarker field was launched with great enthusiasm because MS revealed that blood contains a rich library of candidate biomarkers. However, biomarker research has not yet delivered on its promise due to several limitations: (i) improper sample handling and tracking as well as limited sample availability in the pediatric population, (ii) omission of appropriate controls in original study designs, (iii) lability and low abundance of interesting biomarkers in blood, and (iv) the inability to mechanistically tie biomarker presence to disease biology. These limitations as well as successful strategies to overcome them are discussed in this review. Several advances in biomarker discovery and validation have been made in hematopoietic stem cell transplantation, the current most effective tumor immunotherapy, and these could serve as examples for other conditions. This review provides fresh optimism that biomarkers clinically relevant in pediatrics are closer to being realized based on: (i) a uniform protocol for low-volume blood collection and preservation, (ii) inclusion of well-controlled independent cohorts, (iii) novel technologies and instrumentation with low analytical sensitivity, and (iv) integrated animal models for exploring potential biomarkers and targeted therapies.

Original languageEnglish
Pages (from-to)837-850
Number of pages14
JournalProteomics - Clinical Applications
Volume8
Issue number11-12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Pediatrics
Hematopoietic Stem Cell Transplantation
Biomarkers
Stem cells
Proteomics
Blood
Hope
Blood Preservation
Health care
Health Care Costs
Immunotherapy
Libraries
Tumors
Animals
Animal Models
Availability
Technology

Keywords

  • Biomarkers
  • Graft-versus-host disease
  • Hematopoietic stem cell transplantation
  • Pediatrics
  • Risk stratification

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Opportunities and challenges of proteomics in pediatric patients : Circulating biomarkers after hematopoietic stem cell transplantation as a successful example. / Paczesny, Sophie; Duncan, Christine; Jacobsohn, David; Krance, Robert; Leung, Kathryn; Carpenter, Paul; Bollard, Catherine; Renbarger, Jamie; Cooke, Kenneth.

In: Proteomics - Clinical Applications, Vol. 8, No. 11-12, 01.12.2014, p. 837-850.

Research output: Contribution to journalArticle

Paczesny, Sophie ; Duncan, Christine ; Jacobsohn, David ; Krance, Robert ; Leung, Kathryn ; Carpenter, Paul ; Bollard, Catherine ; Renbarger, Jamie ; Cooke, Kenneth. / Opportunities and challenges of proteomics in pediatric patients : Circulating biomarkers after hematopoietic stem cell transplantation as a successful example. In: Proteomics - Clinical Applications. 2014 ; Vol. 8, No. 11-12. pp. 837-850.
@article{bb176565666a48e2b70aea23c9568938,
title = "Opportunities and challenges of proteomics in pediatric patients: Circulating biomarkers after hematopoietic stem cell transplantation as a successful example",
abstract = "Biomarkers have the potential to improve diagnosis and prognosis, facilitate-targeted treatment, and reduce health care costs. Thus, there is great hope that biomarkers will be integrated in all clinical decisions in the near future. A decade ago, the biomarker field was launched with great enthusiasm because MS revealed that blood contains a rich library of candidate biomarkers. However, biomarker research has not yet delivered on its promise due to several limitations: (i) improper sample handling and tracking as well as limited sample availability in the pediatric population, (ii) omission of appropriate controls in original study designs, (iii) lability and low abundance of interesting biomarkers in blood, and (iv) the inability to mechanistically tie biomarker presence to disease biology. These limitations as well as successful strategies to overcome them are discussed in this review. Several advances in biomarker discovery and validation have been made in hematopoietic stem cell transplantation, the current most effective tumor immunotherapy, and these could serve as examples for other conditions. This review provides fresh optimism that biomarkers clinically relevant in pediatrics are closer to being realized based on: (i) a uniform protocol for low-volume blood collection and preservation, (ii) inclusion of well-controlled independent cohorts, (iii) novel technologies and instrumentation with low analytical sensitivity, and (iv) integrated animal models for exploring potential biomarkers and targeted therapies.",
keywords = "Biomarkers, Graft-versus-host disease, Hematopoietic stem cell transplantation, Pediatrics, Risk stratification",
author = "Sophie Paczesny and Christine Duncan and David Jacobsohn and Robert Krance and Kathryn Leung and Paul Carpenter and Catherine Bollard and Jamie Renbarger and Kenneth Cooke",
year = "2014",
month = "12",
day = "1",
doi = "10.1002/prca.201400033",
language = "English",
volume = "8",
pages = "837--850",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "11-12",

}

TY - JOUR

T1 - Opportunities and challenges of proteomics in pediatric patients

T2 - Circulating biomarkers after hematopoietic stem cell transplantation as a successful example

AU - Paczesny, Sophie

AU - Duncan, Christine

AU - Jacobsohn, David

AU - Krance, Robert

AU - Leung, Kathryn

AU - Carpenter, Paul

AU - Bollard, Catherine

AU - Renbarger, Jamie

AU - Cooke, Kenneth

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Biomarkers have the potential to improve diagnosis and prognosis, facilitate-targeted treatment, and reduce health care costs. Thus, there is great hope that biomarkers will be integrated in all clinical decisions in the near future. A decade ago, the biomarker field was launched with great enthusiasm because MS revealed that blood contains a rich library of candidate biomarkers. However, biomarker research has not yet delivered on its promise due to several limitations: (i) improper sample handling and tracking as well as limited sample availability in the pediatric population, (ii) omission of appropriate controls in original study designs, (iii) lability and low abundance of interesting biomarkers in blood, and (iv) the inability to mechanistically tie biomarker presence to disease biology. These limitations as well as successful strategies to overcome them are discussed in this review. Several advances in biomarker discovery and validation have been made in hematopoietic stem cell transplantation, the current most effective tumor immunotherapy, and these could serve as examples for other conditions. This review provides fresh optimism that biomarkers clinically relevant in pediatrics are closer to being realized based on: (i) a uniform protocol for low-volume blood collection and preservation, (ii) inclusion of well-controlled independent cohorts, (iii) novel technologies and instrumentation with low analytical sensitivity, and (iv) integrated animal models for exploring potential biomarkers and targeted therapies.

AB - Biomarkers have the potential to improve diagnosis and prognosis, facilitate-targeted treatment, and reduce health care costs. Thus, there is great hope that biomarkers will be integrated in all clinical decisions in the near future. A decade ago, the biomarker field was launched with great enthusiasm because MS revealed that blood contains a rich library of candidate biomarkers. However, biomarker research has not yet delivered on its promise due to several limitations: (i) improper sample handling and tracking as well as limited sample availability in the pediatric population, (ii) omission of appropriate controls in original study designs, (iii) lability and low abundance of interesting biomarkers in blood, and (iv) the inability to mechanistically tie biomarker presence to disease biology. These limitations as well as successful strategies to overcome them are discussed in this review. Several advances in biomarker discovery and validation have been made in hematopoietic stem cell transplantation, the current most effective tumor immunotherapy, and these could serve as examples for other conditions. This review provides fresh optimism that biomarkers clinically relevant in pediatrics are closer to being realized based on: (i) a uniform protocol for low-volume blood collection and preservation, (ii) inclusion of well-controlled independent cohorts, (iii) novel technologies and instrumentation with low analytical sensitivity, and (iv) integrated animal models for exploring potential biomarkers and targeted therapies.

KW - Biomarkers

KW - Graft-versus-host disease

KW - Hematopoietic stem cell transplantation

KW - Pediatrics

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=84912522538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912522538&partnerID=8YFLogxK

U2 - 10.1002/prca.201400033

DO - 10.1002/prca.201400033

M3 - Article

C2 - 25196024

AN - SCOPUS:84912522538

VL - 8

SP - 837

EP - 850

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 11-12

ER -